← Back to Home

FDA Reviews 30 Years of AAV Gene Therapy Submissions: Manufacturing Quality and Safety Assessment Emerge as Hurdles

As gene therapy moves from experimental concept to human trials, hurdles often lie in the details of manufacturing, testing, and risk management. FDA researchers reviewed three decades of submissions, highlighting review challenges at different stages of development.

By SURL BioNews

Whether a gene therapy can enter human trials depends not only on the therapeutic concept, but also on whether manufacturing quality and safety evidence are adequately prepared. FDA researchers reviewed three decades of adeno-associated virus (AAV) gene therapy submissions and found that development activity increased rapidly, while the issues prompting regulatory holds varied by development stage.

The analysis, published on November 12 in *Nature Biotechnology*, was written by researchers at the FDA’s Center for Biologics Evaluation and Research (CBER). The supplementary methods state that the data cover AAV investigational new drug (IND) applications from 1995 through August 2025, excluding applications for single-patient use and focusing on development programs with broader potential for clinical application.

The analysis figures show that chemistry, manufacturing, and controls (CMC) issues featured prominently at initial submission, involving administration device information, test method development and verification, and matters such as contamination and adventitious agents. These details remind developers that clearly demonstrating product quality is also an important condition for starting a trial.

At the preclinical and clinical stages, safety assessment figured more prominently. Preclinical issues included study design, data integrity, and toxicity findings; at the clinical stage, risk assessment, serious adverse event management, and monitoring were more prominent. For development teams, this review can help identify evidence gaps that should be addressed early at each stage.

However, the “number of issues” in the figures cannot be treated directly as the number of affected therapies. The researchers examined each hold letter and classified each listed item separately, so a single application could involve multiple issues. These records also cannot be used on their own to estimate therapies’ ultimate success rates or compare the safety of different products.

This is a review of regulatory experience, rather than a new trial of treatment efficacy. The publicly accessible page and supplementary materials allow verification of the study’s scope and main analytical methods, but the main text remains behind a subscription paywall, limiting interpretation of the detailed results. The authors also state that the views expressed do not necessarily represent the FDA’s positions or policies; developers can use the review as a reference when preparing review materials, rather than as new regulatory requirements.

References

  1. Nature Biotechnology, Published online: 2026-11-12; | doi:10.1038/s41587-026-03378-9